CMAJ • June 22, 2004; 170 (13). doi:10.1503/cmaj.1031335.
© 2004 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow [Animation]
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walsh, S. R.A.
Right arrow Articles by Shear, N. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsh, S. R.A.
Right arrow Articles by Shear, N. H.
Related Collections
Right arrow Dermatology

Review
Synthèse

Psoriasis and the new biologic agents: interrupting a T-AP dance

Scott R.A. Walsh and Neil H. Shear

From the Department of Medicine, Divisions of Dermatology (Walsh, Shear) and Clinical Pharmacology (Shear), Sunnybrook and Women's College Health Sciences Centre, University of Toronto, Toronto, Ont.

Abstract

PSORIASIS IS AN IMMUNE-MEDIATED SKIN DISEASE in which chronic T-cell stimulation by antigen-presenting cells (APC) occurs in the skin. This interplay between the T-cell and APC has been likened to a "T-AP dance" where specific steps must occur in sequence to result in T-cell activation and the disease phenotype; otherwise T-cell anergy would occur. Several novel engineered proteins designed to block specific steps in immune activation (biologic agents) have demonstrated efficacy in the treatment of psoriasis. These agents include fusion proteins, monoclonal antibodies and recombinant cytokines. These medications act at specific steps during the T-AP dance either to inhibit T-cell activation, costimulation and subsequent proliferation of T-cells, lead to immune deviation or induce specific cytokine blockades. The potential increased selectivity for specific pathways in immune activation, clinical efficacy and relative safety of these new agents offers an alternative for the treatment of moderate to severe psoriasis.




This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
J. K Jordan
Efalizumab for the Treatment of Moderate to Severe Plaque Psoriasis
Ann. Pharmacother., September 1, 2005; 39(9): 1476 - 1482.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
E. Wooltorton
A call for video images: medicine in real time
Can. Med. Assoc. J., June 22, 2004; 170(13): 1931 - 1931.
[Full Text] [PDF]